诺和诺德：2025年诺和诺德营收增长6%至3091亿丹麦克朗，大中国区罕见病领域销售以CER计算同比增长84%

Core Insights - Novo Nordisk reported a 6% increase in sales in Danish kroner for 2025, and a 10% increase at constant exchange rates, reaching 309.1 billion Danish kroner [1] Sales Performance - Sales in the Greater China region grew by 5% at constant exchange rates, primarily driven by the growth in obesity treatment products [1] - Sales in the rare disease segment in Greater China increased by 84% at constant exchange rates, mainly due to growth in the rare blood disorders area [1] Regulatory Approvals and Product Updates - The China National Medical Products Administration approved the cardiovascular indication for Novo's drug, Ozempic, based on the SELECT study [1] - Novo Nordisk submitted data from the SOUL cardiovascular outcomes trial for oral semaglutide to update the label for its drug, Rybelsus, for type 2 diabetes patients [1] Shareholder Returns - The board proposed a dividend of 7.95 Danish kroner per share for the end of 2025, totaling 11.70 Danish kroner for the entire year [1] - A new share buyback program of up to 15 billion Danish kroner was also announced [1]